Internal Medicine, Pulmonary Disease · Arecibo, PR
NPI
1871595694
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
540 Ave Miramar, Suite # 4
Arecibo, PR, 00612
Phone (787) 880-6122
Medicare paid, 2024
$8,970
156 services
Medicare patients, 2024
34
Average age 77
Drug cost, 2024
$2.7M
10,069 prescriptions
Company payments, 2025
$659
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William Villanueva-Bosque was code 99213 (office e&m - established), 80 times for 33 patients. In total William Villanueva-Bosque billed 156 services in 6 codes, and Medicare paid $8,970.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-09-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 80 | 33 | $70.38 | $5,630 |
| 94060 Pulmonary Function Testing | Office | 23 | 22 | $30.26 | $696 |
| 94727 Pulmonary Function Testing | Office | 20 | 20 | $34.69 | $694 |
| 94729 Pulmonary Function Testing | Office | 20 | 20 | $44.08 | $882 |
By year: 2022 $11K for 181 services; 2023 $7,401 for 135 services; 2024 $8,970 for 156 services.
Medicare prescription drug claims, 2024
In 2024, the drug William Villanueva-Bosque prescribed most often to Medicare patients was Montelukast Sodium, with 2,545 prescriptions and refills. In total William Villanueva-Bosque wrote 10,069 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 2,545 | 3,428 | 487 | $22K |
| Fluticasone Propionate Generic | 1,272 | 1,376 | 257 | $19K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 784 | 855 | 498 | $36K |
| Fluticasone Propionate Hfa Fluticasone Propionate | 538 | 548 | 126 | $115K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 507 | 620 | 126 | $131K |
| Breo Ellipta Fluticasone/Vilanterol | 450 | 457 | 78 | $187K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 444 | 456 | 72 | $302K |
| Qvar Redihaler Beclomethasone Dipropionate | 371 | 377 | 82 | $89K |
| Symbicort Budesonide/Formoterol Fumarate | 354 | 358 | 95 | $84K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 330 | 334 | 59 | $44K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 292 | 304 | 55 | $149K |
| Desloratadine Generic | 222 | 230 | 43 | $4,541 |
| Roflumilast Generic | 174 | 212 | 25 | $12K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 170 | 175 | 32 | $83K |
| Spiriva Respimat Tiotropium Bromide | 164 | 164 | 34 | $87K |
Brand drugs: 4,602 claims; generic drugs: 5,450 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William Villanueva-Bosque $659 ($659 in general payments such as food, travel and fees) from 6 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $232.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.